OrthoPediatrics (KIDS) Hisse Özeti
Bir tıbbi cihaz şirketi olan OrthoPediatrics Corp. ortopedik rahatsızlıkları olan çocuklar için anatomik olarak uygun implantlar, aletler ve özel diş telleri tasarlamakta, geliştirmekte ve Amerika Birleşik Devletleri'nde ve uluslararası alanda pazarlamaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 0/6 |
KIDS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
OrthoPediatrics Corp. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$25.65 |
| 52 Haftanın En Yüksek Seviyesi | US$26.74 |
| 52 Haftanın En Düşük Seviyesi | US$14.42 |
| Beta | 0.96 |
| 1 Aylık Değişim | 35.93% |
| 3 Aylık Değişim | 39.63% |
| 1 Yıllık Değişim | 26.98% |
| 3 Yıllık Değişim | -29.34% |
| 5 Yıllık Değişim | -60.86% |
| Halka arzdan bu yana değişim | 33.45% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Aug 12
KIDS: Trauma Strength And New Products Will Mask Lingering Scoliosis Risk
Analysts have lifted their fair value estimate for OrthoPediatrics to $22 from $20, citing a recent Q2 performance that they view as supported by Trauma & Deformity growth, new product launches, and what they describe as temporary Scoliosis headwinds that affected reported demand. What’s in the News for OrthoPediatrics OrthoPediatrics updated its full year 2026 outlook and set revenue guidance in a range of US$265.0 million to US$269.0 million, compared with a prior range of US$263.0 million to US$267.0 million.Anlatı Güncellemesi • Jul 17
KIDS: Cash Flow And New Partnerships Will Balance Mixed Market Expectations
Analysts now estimate OrthoPediatrics' fair value at approximately $20.00 per share, up from $17.00, citing updated assumptions related to revenue growth, discount rate, profit margin, and a higher future P/E multiple reflected in recent price target revisions from the Street. Analyst Commentary Recent Street research on OrthoPediatrics shows a mix of views around the stock's valuation, with some price targets adjusted upward and others trimmed.Recent updates
Anlatı Güncellemesi • Aug 12
KIDS: Trauma Strength And New Products Will Mask Lingering Scoliosis Risk
Analysts have lifted their fair value estimate for OrthoPediatrics to $22 from $20, citing a recent Q2 performance that they view as supported by Trauma & Deformity growth, new product launches, and what they describe as temporary Scoliosis headwinds that affected reported demand. What’s in the News for OrthoPediatrics OrthoPediatrics updated its full year 2026 outlook and set revenue guidance in a range of US$265.0 million to US$269.0 million, compared with a prior range of US$263.0 million to US$267.0 million.Anlatı Güncellemesi • Jul 17
KIDS: Cash Flow And New Partnerships Will Balance Mixed Market Expectations
Analysts now estimate OrthoPediatrics' fair value at approximately $20.00 per share, up from $17.00, citing updated assumptions related to revenue growth, discount rate, profit margin, and a higher future P/E multiple reflected in recent price target revisions from the Street. Analyst Commentary Recent Street research on OrthoPediatrics shows a mix of views around the stock's valuation, with some price targets adjusted upward and others trimmed.
Anlatı Güncellemesi • Jun 24
KIDS: Pediatric Orthopedic Execution And 2026 Guidance Will Drive Upside Potential
OrthoPediatrics’ analyst price target has shifted modestly, with a recent $1 upward move and $3 downward moves leaving the Street view recalibrated as analysts weigh updated assumptions on discount rates, profit margins, and future P/E expectations. Analyst Commentary Recent Street research on OrthoPediatrics reflects a mix of optimism and caution as analysts reassess their models, which has led to both upward and downward adjustments to the stock’s price target.Anlatı Güncellemesi • Jun 08
KIDS: 2026 Guidance Delivery Will Shape Upside From Pediatric Orthopedic Focus
Analysts have made a modest net reduction of $2 in their price targets for OrthoPediatrics, reflecting updated views on the stock that incorporate both more cautious and more optimistic research opinions. Analyst Commentary Recent research on OrthoPediatrics shows a mixed but measured stance, with one firm trimming its price target and another lifting theirs.Anlatı Güncellemesi • May 24
KIDS: 2026 Product Launches And Guidance Execution Will Drive Upside Potential
Narrative Update on OrthoPediatrics The updated analyst price target for OrthoPediatrics edges up from about $24.00 to roughly $24.67, as analysts factor in recent price target revisions across the Street and modest adjustments to long term growth, profitability, and future P/E assumptions. Analyst Commentary Recent Street commentary around OrthoPediatrics reflects a mix of optimism about the company’s long term opportunity and caution around execution and valuation, which together shape the modestly higher blended price target.Anlatı Güncellemesi • May 07
KIDS: Cash Flow And 2026 Launches Will Offset More Cautious Long Range Assumptions
The analyst price target for OrthoPediatrics has been revised from $20 to $17 as analysts factor in slightly lower long range assumptions for revenue growth, profit margins, and future P/E, while still highlighting prior commentary around solid EBITDA, free cash flow, and contributions from upcoming product launches. Analyst Commentary Recent research shows a mix of views on OrthoPediatrics, with some analysts trimming expectations even as others highlight prior strength in EBITDA, free cash flow, and potential contributions from future product launches.
Anlatı Güncellemesi • Apr 22
KIDS: Solid Cash Generation And 2026 Launches Will Support Higher Upside
Narrative Update on OrthoPediatrics The Street price targets for OrthoPediatrics have nudged higher, with moves such as Truist's shift to $20 from $19 and Stifel's to $22 from $20, as analysts point to solid Q4 EBITDA, better free cash flow, and expected contributions from new product launches, along with confidence in the company's long-range revenue outlook of 12%. Analyst Commentary Recent research updates highlight a cluster of positive shifts in sentiment around OrthoPediatrics, centered on solid Q4 execution and growing confidence in the company’s long term revenue framework.Anlatı Güncellemesi • Apr 07
KIDS: Solid Cash Flow And 2026 Launches Will Support Long Range Outlook
Analyst price targets for OrthoPediatrics have ticked higher, with recent moves such as Truist lifting its target to $20 and Stifel to $22. These changes reflect analyst views that solid Q4 EBITDA, free cash flow and potential contributions from future product launches support the company’s long range revenue outlook.Anlatı Güncellemesi • Mar 24
KIDS: Solid Cash Generation And 2026 Launches Are Expected To Drive Upside
Analyst price targets for OrthoPediatrics have moved higher by $1 to a range of $20 to $22. This reflects analyst views that solid recent EBITDA and free cash flow, along with expected contributions from new products in 2026, support the company's long range 12% revenue outlook and a slightly higher fair value estimate.Anlatı Güncellemesi • Mar 09
KIDS: Solid Cash Flow And 2026 Launches Will Shape Balanced Outlook
Narrative Update: OrthoPediatrics The analyst price target for OrthoPediatrics has moved from $19 to $20. This change reflects analysts' views that recent solid Q4 EBITDA and free cash flow, along with expectations for contributions from planned product launches and long-range revenue growth, support a modestly higher fair value and a slightly higher future P/E assumption.Anlatı Güncellemesi • Feb 22
KIDS: Execution On 2026 Revenue Guidance Will Support Upside Potential
Analysts have trimmed their price target on OrthoPediatrics slightly to $24.00 from $24.13, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that remain broadly supportive of the positive view reflected in recent Street research. Analyst Commentary Recent Street commentary frames OrthoPediatrics as a higher risk, higher reward idea, where execution on growth plans and disciplined cost control are key to justifying the updated US$24.00 price target.Anlatı Güncellemesi • Feb 08
KIDS: Higher Margin Outlook Will Support Bullish Long Term Opportunity
Analysts have trimmed their price target on OrthoPediatrics by $3 to $19, citing updated assumptions for slightly slower revenue growth, a modestly higher discount rate, and a lower future P/E multiple, even though projected profit margins are set at a higher level. Analyst Commentary Even with higher projected profit margins in current models, some bearish analysts remain cautious on OrthoPediatrics.Anlatı Güncellemesi • Jan 25
KIDS: Revenue Visibility And Margin Progress Are Expected To Drive Long Term Upside
Analysts have lowered their price target on OrthoPediatrics, with one firm cutting its target to $26 from $42 as they factor in updated expectations for revenue growth and profitability, even as the company guides to revenue growth of over 12% over the next few years. Analyst Commentary Bullish analysts see the recent price target reset as more of a recalibration than a complete shift in sentiment.Anlatı Güncellemesi • Jan 11
KIDS: Reset Execution Expectations Should Support Upside From Revised Growth Outlook
Analysts have nudged their price target on OrthoPediatrics lower to about US$24.13 per share from roughly US$24.14, citing slightly reduced revenue growth and profit margin assumptions following recent quarterly results and updated company guidance around revenue growth of over 12% in the coming years. Analyst Commentary Analysts are parsing the latest update on OrthoPediatrics with a mix of optimism around growth and caution around execution and profitability.Anlatı Güncellemesi • Dec 24
KIDS: Core High Margin Segments Are Expected To Drive Long Term Upside
Analysts have reduced their price target on OrthoPediatrics from about $42 to roughly $33, citing lower long term revenue growth assumptions and a modestly higher discount rate, despite resilient margins and confidence in the company’s core high margin segments. Analyst Commentary Bullish analysts acknowledge that the recent price target reductions reflect tempered expectations for near term growth, but they continue to frame OrthoPediatrics as a long term execution story with attractive end market exposure.Anlatı Güncellemesi • Dec 10
KIDS: Reset Expectations Will Support Upside From Core High-Margin Franchise
Analysts trimmed their OrthoPediatrics price targets by roughly $6 to $10 per share across the Street, citing lowered revenue growth forecasts, below consensus Q3 results, and more conservative long term guidance, even as they maintained confidence in the company’s core, higher margin businesses. Analyst Commentary Street research following OrthoPediatrics' preliminary Q3 update reflects a mix of near term caution and longer term optimism, with price targets reset lower but most ratings remaining positive.Anlatı Güncellemesi • Nov 26
KIDS: Revenue Miss Expected To Set Up Double-Digit Upside Over The Next Year
Analysts have lowered their price targets for OrthoPediatrics by a wide margin, with several firm targets now in the $18 to $34 range. They cite recent revenue shortfalls and a more cautious growth outlook, despite continued confidence in the company's long-term fundamentals.Analiz Makalesi • Nov 25
OrthoPediatrics (NASDAQ:KIDS) Is Making Moderate Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Anlatı Güncellemesi • Nov 08
KIDS: Recent Revenue Shortfall Will Set Up Potential Longer-Term Surprise
OrthoPediatrics’ analyst price target has been reduced from approximately $26.29 to $24.14, as analysts cite more conservative revenue growth forecasts and recent performance shortfalls. This adjustment comes despite ongoing long-term confidence in the company’s fundamentals.Anlatı Güncellemesi • Oct 25
Expanding Global Reach Will Support Long-Term Outlook Amid Revenue Headwinds
Analysts have lowered their price targets for OrthoPediatrics, with targets dropping by $3 to $12 per share. They cite recent revenue shortfalls and reduced guidance, though many continue to highlight strength in the company’s core business fundamentals and long-term outlook.Anlatı Güncellemesi • Oct 11
International Clinic Openings And Product Launches Will Expand Global Reach
OrthoPediatrics’ consensus analyst price target has dropped sharply from approximately $33.86 to $26.29 per share. Analysts cite weaker-than-expected revenues due to challenges in select markets and product categories, although the company continues to demonstrate strength in core business fundamentals.Analiz Makalesi • Sep 26
Investors Holding Back On OrthoPediatrics Corp. (NASDAQ:KIDS)
You may think that with a price-to-sales (or "P/S") ratio of 2x OrthoPediatrics Corp. ( NASDAQ:KIDS ) is a stock worth...Anlatı Güncellemesi • Aug 08
International Clinic Openings And Product Launches Will Expand Global Reach
OrthoPediatrics' valuation outlook is stable, with both the future P/E and net profit margin essentially unchanged, resulting in the consensus analyst price target holding steady at $33.86. What's in the News Expanded the OrthoPediatrics Specialty Bracing division with new clinics in California, Ohio, Colorado, New York, and internationally into Ireland, enhancing presence in key hospitals and entering new markets.Analiz Makalesi • Apr 08
Is OrthoPediatrics (NASDAQ:KIDS) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Yeni Anlatı • Mar 26
Pediatric Orthopedic Bracing Expansion Will Secure Market Leadership
Strategic focus on pediatric specialty bracing and product expansion aims for market dominance, improving EBITDA and future earnings growth.Analiz Makalesi • Mar 06
OrthoPediatrics Corp.'s (NASDAQ:KIDS) Shares Not Telling The Full Story
There wouldn't be many who think OrthoPediatrics Corp.'s ( NASDAQ:KIDS ) price-to-sales (or "P/S") ratio of 3x is worth...Analiz Makalesi • Nov 05
Investors Still Waiting For A Pull Back In OrthoPediatrics Corp. (NASDAQ:KIDS)
You may think that with a price-to-sales (or "P/S") ratio of 4x OrthoPediatrics Corp. ( NASDAQ:KIDS ) is a stock to...Analiz Makalesi • Aug 09
The OrthoPediatrics Corp. (NASDAQ:KIDS) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders might have noticed that OrthoPediatrics Corp. ( NASDAQ:KIDS ) filed its quarterly result this time last...Analiz Makalesi • Aug 02
Shareholders Should Be Pleased With OrthoPediatrics Corp.'s (NASDAQ:KIDS) Price
OrthoPediatrics Corp.'s ( NASDAQ:KIDS ) price-to-sales (or "P/S") ratio of 4.5x may not look like an appealing...Analiz Makalesi • May 09
OrthoPediatrics Corp. (NASDAQ:KIDS) Just Reported And Analysts Have Been Lifting Their Price Targets
As you might know, OrthoPediatrics Corp. ( NASDAQ:KIDS ) just kicked off its latest quarterly results with some very...Analiz Makalesi • May 07
OrthoPediatrics (NASDAQ:KIDS) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analiz Makalesi • Apr 10
Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S
With a price-to-sales (or "P/S") ratio of 4.9x OrthoPediatrics Corp. ( NASDAQ:KIDS ) may be sending bearish signals at...Analiz Makalesi • Dec 20
Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S
OrthoPediatrics Corp.'s ( NASDAQ:KIDS ) price-to-sales (or "P/S") ratio of 5.5x may look like a poor investment...Hissedar Getirileri
| KIDS | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | 3.4% | 0.4% | -1.5% |
| 1Y | 27.0% | -12.6% | 17.8% |
Getiri vs. Endüstri: KIDS geçen yıl % -12.6 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: KIDS geçen yıl % 17.8 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| KIDS volatility | |
|---|---|
| KIDS Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: KIDS son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: KIDS 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2006 | 602 | David Bailey | www.orthopediatrics.com |
Bir tıbbi cihaz şirketi olan OrthoPediatrics Corp., Amerika Birleşik Devletleri'nde ve uluslararası alanda ortopedik rahatsızlıkları olan çocuklar için anatomik olarak uygun implantlar, aletler ve özel diş telleri tasarlamakta, geliştirmekte ve pazarlamaktadır. Şirket, pediatrik travma ve deformite düzeltme ürünleri; çocuklarda omurga deformitesinin tedavisi için skolyoz prosedürleri; ve spor hekimliği ve diğer ürünler sunmaktadır. Ürünleri PediLoc, PediPlates, kanüllü vidalar, PediFlex çivi, PediNail, PediLoc Tibia, ACL Rekonstrüksiyon Sistemi, Kilitli Kanüllü Bıçak, Kilitli Proksimal Femur, Spica Masaları, RESPONSE Omurga, BandLoc, Pediatrik Çivileme Platformu | Femur'dan oluşmaktadır, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM ve Boston Brace 3D.
OrthoPediatrics Corp. Temel Bilgiler Özeti
| KIDS temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$669.72m |
| Kazançlar(TTM) | -US$39.73m |
| Gelir(TTM) | US$252.72m |
2.6x
P/S Oranı-16.9x
F/K OranıKIDS aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| KIDS gelir tablosu (TTM) | |
|---|---|
| Gelir | US$252.72m |
| Gelir Maliyeti | US$66.59m |
| Brüt Kâr | US$186.14m |
| Diğer Giderler | US$225.86m |
| Kazançlar | -US$39.73m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -1.52 |
| Brüt Marj | 73.65% |
| Net Kâr Marjı | -15.72% |
| Borç/Özkaynak Oranı | 29.7% |
KIDS uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/23 02:02 |
| Gün Sonu Hisse Fiyatı | 2026/08/21 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
OrthoPediatrics Corp. 11 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |
| David Turkaly | Citizens JMP Securities, LLC |